Comparing Opus Genetics (IRD) and Its Competitors

Opus Genetics (NASDAQ:IRD) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Opus Genetics to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Opus Genetics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Opus Genetics Competitors	9782	15053	45297	1571	2.54

Opus Genetics presently has a consensus target price of $12.71, indicating a potential upside of 223.52%. As a group, “Biotechnology” companies have a potential upside of 97.60%. Given Opus Genetics’ stronger consensus rating and higher possible upside, research analysts clearly believe Opus Genetics is more favorable than its rivals.

Insider & Institutional Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Opus Genetics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Opus Genetics Competitors	-9,046.59%	-199.78%	-30.61%

Volatility & Risk

Opus Genetics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Opus Genetics’ rivals have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Opus Genetics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$14.20 million	-$49.59 million	-2.91
Opus Genetics Competitors	$691.13 million	$10.43 million	-10.02

Opus Genetics’ rivals have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Opus Genetics Company Profile

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.